zoledronic acid (zoledronate)

01/01/2004 - "Zoledronic acid was significantly more effective than placebo on most efficacy measures in patients with bone metastases secondary to other solid tumours (e.g. "
12/01/2002 - "Zoledronic acid is the first and only bisphosphonate to be proved effective in patients with all types of bone lesions, from osteolytic to osteoblastic, and therefore represents an important therapeutic advancement in the treatment of bone metastases."
01/01/2015 - "BS is effective for assessing the response of bone metastasis to therapy in patients during zoledronic acid treatment."
04/01/2012 - "Zoledronic acid, although underutilized in genitourinary malignancies, has long been the mainstay of treatment in patients with bone metastases, and can also help preserve bone during anticancer therapy. "
08/01/2014 - "However, zoledronic acid does reduce the development of bone metastases and, for women with established menopause, improved disease outcomes. "

05/01/2012 - "Zoledronic acid was found to be cost effective in all European countries across all three indications but not in the sole global prostate cancer analysis. "
01/01/2010 - "Zoledronic acid treatment promoted effective osseous protection against the natural demineralization process in patients with prostate cancer recurrence submitted to ADT."
11/01/2009 - "Zoledronic acid improved bone mineral density in patients with M0 prostate cancer on androgen deprivation therapy for 1 year or less, or greater than 1 year. "
03/01/2007 - "Zoledronic acid (4 mg intravenously every 3 months) was safe and effective in preventing bone loss and reducing bone turnover in patients with prostate cancer when initiated during the first year of androgen deprivation therapy; patients with low baseline BMD experienced the greatest benefit."
10/01/2002 - "The objective of this study was to evaluate the efficacy of zoledronate in limiting the formation and/or progression of osteoblastic lesions produced by the injection of known prostate cancer cells (LAPC-9 and PC-3 cells) into the tibia of SCID mice. "

02/01/2014 - "However, RANKL inhibition reduced skeletal growth of MDA-231-RANK tumors to a significantly greater extent than zoledronic acid, indicating that skeletal growth of RANK-positive tumors is also driven by direct RANKL effects. "
06/01/2009 - "At day 33, both combination therapies and zoledronic acid monotherapy provided significant reduction in total tumor burden and tumor infiltration of hindlimbs by histomorphometry (p<0.05). "
08/01/2007 - "On the basis of stimulating data on animals reporting that weekly regimens of zoledronic acid (ZA) were effective in reducing skeletal tumor burden, we designed a study on humans to investigate the potential antiangiogenic role of a weekly low-dose therapy with ZA in patients with malignancies. "
10/13/2015 - "Our work proposes nanoparticle formulations of zoledronic acid as the first not toxic metabolic modifiers, effective against MDR tumors. "
03/01/2010 - "Development of new treatment for metastatic bone tumors is awaited, but there is a possibility of inappropriate use as with zoledronic acid because of lack of knowledge and experience. "

11/01/2011 - "Indeed, current data support the possibility that zoledronic acid might be most effective for improving disease-free survival in the adjuvant breast cancer setting in women who are postmenopausal or have endocrine therapy-induced menopause."
02/01/2012 - "Clinical data from large, phase 3 trials (ie, ABCSG-12, ZO-FAST, and AZURE) demonstrate significantly improved disease-free survival with zoledronic acid in some patient populations with early breast cancer. "
11/01/2011 - "Moreover, clinical data from the ABCSG-12 and ZO-FAST trials demonstrate significantly improved disease-free survival with zoledronic acid in the adjuvant breast cancer setting. "
07/18/2012 - "In early-stage (stages I, II, and III) breast cancer, treatment with the bisphosphonate zoledronic acid has shown improvements in disease-free and overall survival. "
06/26/2012 - "Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer."

12/01/2007 - "Tentatively, we suggest that the zoledronic acid antitumoral activity in multiple myeloma is also sustained by antiangiogenesis, which would partly account for its therapeutic efficacy in multiple myeloma."
06/25/2011 - "Safety and efficacy of zoledronic acid in multiple myeloma."
06/25/2011 - "Safety and efficacy of zoledronic acid in multiple myeloma."
09/01/2015 - "Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial."
11/01/2014 - "A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events."